Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter

被引:264
作者
Dingli, D
Peng, KW
Harvey, ME
Greipp, PR
O'Connor, MK
Cattaneo, R
Morris, JC
Russell, SJ
机构
[1] Mayo Clin & Mayo Fdn, Program Mol Med, Rochester, MN USA
[2] Mayo Clin & Mayo Fdn, Div Hematol & Internal Med, Rochester, MN 55905 USA
[3] Mayo Clin & Mayo Fdn, Dept Radiol, Rochester, MN 55905 USA
[4] Mayo Clin & Mayo Fdn, Div Endocrinol & Metab, Rochester, MN 55905 USA
关键词
D O I
10.1182/blood-2003-07-2233
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Edmonston vaccine strain of measles virus (MV-Edm) propagates efficiently in a broad range of human tumor cells, killing them selectively. However, the oncolytic potency of MV-Edm in different human tumor xenograft therapy models is highly variable and there is no convenient way to map the distribution of virus-infected tissues in vivo. To enhance the oncolytic potency of MV-Edm against radiosensitive malignancies and to facilitate noninvasive imaging of infected tissues, we generated a recombinant MV-Edm encoding the human thyroidal iodide symporter (NIS). MV-NIS replicated almost as efficiently as unmodified MV-Edm, and human tumor cells efficiently concentrated radioiodine when infected with MV-NIS. Intratumoral spread of MV-NIS was noninvasively demonstrated by serial gamma-camera imaging of iodine-123 (I-123) Uptake both in MV-sensitive KAS-6/1 myeloma xenografts, which regressed completely after a single intravenous dose of MV-NIS, and in MM1 myeloma xenografts, which were unresponsive to MV-NIS therapy. However, MV-resistant MM1 tumors regressed completely when I-131 was administered 9 days after a single intravenous injection of MV-NIS (radiovirotherapy). I-131 alone had no effect on MM1 tumor growth. While the potential hematopoietic toxicity of this new therapy requires further evaluation, image-guided radiovirotherapy is a promising new approach to the treatment of multiple myeloma, an incurable but highly radiosensitive plasma cell malignancy. Testing in other radiosensitive cancers is warranted. (C) 2004 by The American Society of Hematology.
引用
收藏
页码:1641 / 1646
页数:6
相关论文
共 37 条
[1]   Multiple myeloma [J].
Bataille, R ;
Harousseau, JL .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (23) :1657-1664
[2]   A possible role of CD46 for the protection in vivo of human renal tumor cells from complement-mediated damage [J].
Blok, VT ;
Daha, MR ;
Tijsma, OMH ;
Weissglas, MG ;
van den Broek, LJCM ;
Gorter, A .
LABORATORY INVESTIGATION, 2000, 80 (03) :335-344
[3]   In vivo imaging and radioiodine therapy following sodium iodide symporter gene transfer in animal model of intracerebral gliomas [J].
Cho, JY ;
Shen, DHY ;
Yang, W ;
Williams, B ;
Buckwalter, T ;
La Perle, KMD ;
Hinkle, G ;
Pozderac, R ;
Kloos, R ;
Nagaraja, H ;
Barth, RF ;
Jhiang, SM .
GENE THERAPY, 2002, 9 (17) :1139-1145
[4]   SUCCESSES AND FAILURES IN MEASLES CONTROL [J].
CUTTS, FT ;
MARKOWITZ, LE .
JOURNAL OF INFECTIOUS DISEASES, 1994, 170 :S32-S41
[5]  
Dimopoulos MA, 2000, ACTA ONCOL, V39, P823
[6]  
Dingli D, 2002, CLIN CANCER RES, V8, P3948
[7]   Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid [J].
Donin, N ;
Jurianz, K ;
Ziporen, L ;
Schultz, S ;
Kirschfink, M ;
Fishelson, Z .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2003, 131 (02) :254-263
[8]   THE HUMAN CD46 MOLECULE IS A RECEPTOR FOR MEASLES-VIRUS (EDMONSTON STRAIN) [J].
DORIG, RE ;
MARCIL, A ;
CHOPRA, A ;
RICHARDSON, CD .
CELL, 1993, 75 (02) :295-305
[9]  
DREWINKO B, 1981, BLOOD, V57, P333
[10]   Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice [J].
Grote, D ;
Russell, SJ ;
Cornu, TI ;
Cattaneo, R ;
Vile, R ;
Poland, GA ;
Fielding, AK .
BLOOD, 2001, 97 (12) :3746-3754